debate: optimal salvage therapy for refractory colon cancer? - tas102 or regorafenib
Published 6 years ago • 348 plays • Length 8:44Download video MP4
Download video MP3
Similar videos
-
9:06
debate: is there an optimal treatment for refractory colorectal cancer? - tas-102 or regorafenib
-
7:20
debate: optimal salvage therapy for refractory colon cancer? - immunotherapy
-
4:53
debate: salvage therapy for mcrc? - tas-102 followed by regorafenib
-
12:47
debate: salvage therapy for mcrc? regorafenib followed by tas-102
-
13:46
debate 3: salvage therapy for mcrc? - tas-102
-
7:54
regorafenib vs tas-102 salvage therapy
-
9:12
debate: is there an optimal treatment for refractory colorectal cancer? - immunotherapy
-
11:02
debate 3: salvage therapy for mcrc? - regorafenib
-
17:17
debate: targeted therapy for ras/braf wt left sided colon cancers - egfr antibodies are mandatory
-
8:26
regorafenib in advanced colorectal cancer: dosing strategies
-
2:13
later-line treatment for mcrc: regorafenib or tas-102?
-
8:36
debate: is there an optimal sequence for first-line therapy in mcrc? - yes
-
1:28
dr. overman on distinctions between regorafenib and tas-102 in crc
-
0:57
choosing between tas-102 and regorafenib in colorectal cancer
-
1:16
dr. bekaii-saab on tas-102 and regorafenib in mcrc
-
18:55
emerging treatment options for mcrc patients in the late-line setting
-
8:14
optimizing treatment with regorafenib in metastic colorectal cancer
-
17:33
chemorefractory colorectal cancer
-
35:27
expert perspectives: optimizing late-line therapy for patients with metastatic colorectal cancer